A clinician’s guide to single vs multiple inhaler therapy for COPD

REFERENCES

• Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP
   PubMed Web of Science ®Google Scholar
• Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. doi: 10.3111/13696998.2011.594123
   PubMedGoogle Scholar
• Bogart M, Stanford RH, Laliberté F, et al. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. doi:10.2147/COPD.S184653
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Fixed-dose combination inhalers. Handb Exp Pharmacol. 2017;237:117–129. doi:10.1007/164_2016_66
   PubMedGoogle Scholar
• Lavorini F, Bianco A, Blasi F, et al. What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis. Respir Med. 2020;166:105937. doi:10.1016/j.rmed.2020.105937
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rinaldi B, De Novellis V, Rogliani P, Matera MG. Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. Expert Rev Respir Med. 2022;16(11–12):1205–1212. doi:10.1080/17476348.2023.2167715
   PubMed Web of Science ®Google Scholar
• Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y
   PubMed Web of Science ®Google Scholar
• Vincken W, Levy ML, Scullion J, et al. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res. 2018;4(2):00065–2018. doi: 10.1183/23120541.00065-2018
   PubMedGoogle Scholar
• Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. Expert Opin Drug Deliv. 2009;6(1):91–102. doi: 10.1517/17425240802637862
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017;124:6–14. doi:10.1016/j.rmed.2017.01.006
   PubMed Web of Science ®Google Scholar
• Ahn JH, Chung JH, Shin KC, et al. Critical inhaler handling error is an independent risk factor for frequent exacerbations of chronic obstructive pulmonary disease: interim eesults of a single center prospective study. Int J Chron Obstruct Pulmon Dis. 2019;14:2767–2775. doi:10.2147/COPD.S234774
   PubMed Web of Science ®Google Scholar
• Nash, D. Poor inhaler adherence and techniques – How can we improve it?. Curr Geri Rep. 2021;10(2):66–71. doi: 10.1007/s13670-021-00355-9
   Google Scholar
• Sulku J, Bröms K, Högman M, et al. Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. NPJ Prim Care Respir Med. 2021;31(1):5. doi: 10.1038/s41533-021-00218-y
   PubMedGoogle Scholar
• Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis. 2016;12:59–71. doi:10.2147/COPD.S117196
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein JJ, Kerkhoff AH, et al. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax. 1995;50(11):1183–1187. doi: 10.1136/thx.50.11.1183
   PubMed Web of Science ®Google Scholar
• Khassawneh BY, Al-Ali MK, Alzoubi KH, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324–328.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646. doi: 10.1080/17425247.2020.1739021
   PubMed Web of Science ®Google Scholar
• Chan AHY, Pleasants RA, Dhand R, et al. Digital inhalers for asthma or chronic obstructive pulmonary disease: A scientific perspective. Pulm Ther. 2021;7(2):345–376. doi:10.1007/s41030-021-00167-4
   PubMedGoogle Scholar
• Zhang S, King D, Rosen VM, et al. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823
   PubMed Web of Science ®Google Scholar
• Papi A, Blasi F, Canonica GW, et al. Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage. Eur J Intern Med. 2014;25(8):695–700. doi: 10.1016/j.ejim.2014.06.022
   PubMedGoogle Scholar
• Ferguson GT, Hickey AJ, Dwivedi S Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respir Med. 2018;134:16–23. doi:10.1016/j.rmed.2017.09.012
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Noga B, Vehring R, et al. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3(13):1703–1718. doi: 10.4155/fmc.11.133
   PubMed Web of Science ®Google Scholar
• Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020;17(2):133–144. doi: 10.1080/17425247.2020.1712356
   PubMed Web of Science ®Google Scholar
• Ikeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol. 2012;166(6):1804–1814. doi: 10.1111/j.1476-5381.2012.01881.x
   PubMed Web of Science ®Google Scholar
• Farkas Á, Horváth A, Tomisa G, et al. Do we really target the receptors? Deposition and co-deposition of ICS-LABA fixed combination drugs. Eur J Pharm Sci. 2022;174:106186. doi:10.1016/j.ejps.2022.106186
   PubMedGoogle Scholar
• Usmani OS, Roche N, Jenkins M, Stjepanovic N, Mack P, De Backer W. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: A review of the evidence. Int J Chron Obstruct Pulmon Dis. 2021;16:113–124. doi:10.2147/COPD.S274846
   PubMed Web of Science ®Google Scholar
• Gulati N, Chellappan DK, MacLoughlin R, Dua K, Dureja H. Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects. Life Sci. 2021;285:119969. doi:10.1016/j.lfs.2021.119969
   PubMedGoogle Scholar
• Mortensen NP, Hickey AJ. Targeting inhaled therapy beyond the lungs. Respiration. 2014;88(5):353–354. doi:10.1159/000367852
   PubMedGoogle Scholar
• Cazzola M, Ora J, Calzetta L, Rogliani P, Matera MG. The future of inhalation therapy in chronic obstructive pulmonary disease. Curr Res Pharmacol Drug Discov. 2022;3:100092. doi:10.1016/j.crphar.2022.100092
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi: 10.1124/pr.111.004580
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG. Dual bronchodilation for the treatment of COPD: From bench to bedside. Br J Clin Pharmacol. 2022;88(8):3657–3673. doi:10.1111/bcp.15390
   PubMed Web of Science ®Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest. 2004;126(1):220–237. doi:10.1378/chest.126.1.220
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Facciolo F, et al. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018;19(1):65. doi: 10.1186/s12931-018-0770-7
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9. doi:10.1016/j.pupt.2015.11.004
   PubMed Web of Science ®Google Scholar
• Matera MG, Rinaldi B, Calabrese C, et al. The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro. Respir Res. 2024;25(1):104. doi:10.1186/s12931-024-02710-8
   PubMedGoogle Scholar
• Matera MG, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218–252. doi: 10.1124/pr.119.018150
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Facciolo F, et al. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 2020;177(5):1150–1163. doi: 10.1111/bph.14909
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Facciolo F, et al. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. Pharmacol Res. 2021;172:105801. doi:10.1016/j.phrs.2021.105801
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M, et al. Optimizing the development strategy of combination therapy in respiratory medicine: from isolated airways to patients. Adv Ther. 2019;36(12):3291–3298. doi: 10.1007/s12325-019-01119-w
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Girolami A, et al. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulm Pharmacol Ther. 2021;69:102050. doi:10.1016/j.pupt.2021.102050
   PubMed Web of Science ®Google Scholar
• Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: A retrospective analysis in Spain. Chest. 2022;162(5):1017–1029. doi:10.1016/j.chest.2022.06.033
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Acharya S, Aggarwal B, et al. Clinical concepts for triple therapy use in patients with COPD: A Delphi consensus. Int J Chron Obstruct Pulmon Dis. 2023;18:1853–1866. doi:10.2147/COPD.S424128
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al.. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389(10082):1919–1929. doi: 10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Salvi S, Balki A, Krishnamurthy S, et al. Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ Open Res. 2021;7(3):00255–2021. doi:10.1183/23120541.00255-2021
   PubMedGoogle Scholar
• Yu AP, Guérin A, de Leon DP, et al. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med. 2011;105(12):1861–1871. doi: 10.1016/j.rmed.2011.07.001
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Kendall R, Shukla S, et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: The INTREPID trial. Int J Chron Obstruct Pulmon Dis. 2022;17:2745–2755. doi:10.2147/COPD.S370577
   PubMed Web of Science ®Google Scholar
• Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH. Real-world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice. Int J Chron Obstruct Pulmon Dis. 2021;16:1255–1264. doi:10.2147/COPD.S290773
   PubMed Web of Science ®Google Scholar
• Houben-Wilke S, Augustin IM, Vercoulen JH, et al. COPD stands for complex obstructive pulmonary disease. Eur Respir Rev. 2018;27(148):180027. doi:10.1183/16000617.0027-2018
   PubMed Web of Science ®Google Scholar
• Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008;59(1):443–453. doi: 10.1146/annurev.med.59.062606.122232
   PubMedGoogle Scholar
• Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022;77(4):1105–1113. doi: 10.1111/all.15076
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-122
   PubMed Web of Science ®Google Scholar
• van Zelst CM, Goossens LMA, Witte JA, et al. Stratification of COPD patients towards personalized medicine: reproduction and formation of clusters. Respir Res. 2022;23(1):336. doi:10.1186/s12931-022-02256-7
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Blasi F Can treatable traits be the approach to addressing the complexity and heterogeneity of COPD? Int J Chron Obstruct Pulmon Dis. 2023;18:1959–1964. doi:10.2147/COPD.S428391
   PubMed Web of Science ®Google Scholar
• McDonald VM, Holland AE. Treatable traits models of care. Respirology. 2024;29(1):24–35. doi:10.1111/resp.14644
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. An obvious paradigm: choosing bronchodilators and inhaled corticosteroids for their pharmacologic characteristics. Chest. 2021;160(4):1157–1159. doi: 10.1016/j.chest.2021.06.025
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, et al. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.001
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: A randomized study. Adv Ther. 2017;34(11):2518–2533. doi:10.1007/s12325-017-0626-4
   PubMed Web of Science ®Google Scholar
• Postma DS, Roche N, Colice G, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186. doi:10.2147/COPD.S68289
   PubMed Web of Science ®Google Scholar
• Janson C, Stratelis G, Miller-Larsson A, et al. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064. doi:10.2147/COPD.S143656
   PubMed Web of Science ®Google Scholar
• Wang MT, Lai JH, Huang YL, et al. Comparative effectiveness and safety of different types of inhaled long-acting β2-agonist plus Inhaled long-acting muscarinic antagonist vs inhaled long-acting β2-agonists plus inhaled corticosteroid fixed-dose combinations in COPD a propensity score-inverse probability of treatment weighting cohort study. Chest. 2021;160(4):1255–1270. doi:10.1016/j.chest.2021.05.025
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P. Inhaled medication: which device for which patient? ERS Monogr. 2015;69:213–223.
   Google Scholar
• López-Campos JL, Carrasco Hernández L, Ruiz-Duque B, Reinoso-Arija R, Caballero-Eraso C. Step-up and step-down treatment approaches for COPD: A holistic view of progressive therapies. Int J Chron Obstruct Pulmon Dis. 2021;16:2065–2076. doi:10.2147/COPD.S275943
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:F1000 Faculty Rev-1533. doi:10.12688/f1000research.19811.1
   PubMedGoogle Scholar
• Singh D, Miravitlles M, Vogelmeier C. Chronic obstructive pulmonary disease individualized therapy: tailored approach to symptom management. Adv Ther. 2017;34(2):281–299. doi: 10.1007/s12325-016-0459-6
   PubMed Web of Science ®Google Scholar
• Hoppentocht M, Hagedoorn P, Frijlink HW, et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18–31. doi:10.1016/j.addr.2014.04.004
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, de Abajo FJ, Izquierdo-Alonso JL Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study. Int J Chron Obstruct Pulmon Dis. 2020;15:3291–3302. doi:10.2147/COPD.S281333
   PubMed Web of Science ®Google Scholar
• Matera MG, Rinaldi B, Page C, et al. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018;14(10):1101–1111. doi: 10.1080/17425255.2018.1530215
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Matera MG, et al. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018;17(6):589–596. doi: 10.1080/14740338.2018.1472232
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rogliani P, Hanania N, Cazzola M. Cardiovascular events with the use of long-acting muscarinic receptor antagonists: An analysis of the FAERS database 2020-2023. Lung. 2024;202(2):119–125. doi:10.1007/s00408-024-00677-3
   PubMedGoogle Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541. doi: 10.1517/14740338.2015.1001363
   PubMed Web of Science ®Google Scholar
• Stolz D, Matera MG, Rogliani P, et al. Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022. Breathe (Sheff). 2023;19(2):220267. doi:10.1183/20734735.0267-2022
   PubMedGoogle Scholar
• Hurst JR, Buist AS, Gaga M, et al. Challenges in the implementation of chronic obstructive pulmonary disease guidelines in low- and middle-income countries: an official american thoracic society workshop report. Ann Am Thorac Soc. 2021;18(8):1269–1277. doi: 10.1513/AnnalsATS.202103-284ST
   PubMed Web of Science ®Google Scholar
• Maniscalco M, Martucci M, Fuschillo S, de Felice A, D’Anna SE, Cazzola M. A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: The “progetto PADRE”. Respir Med. 2020;170:105985. doi:10.1016/j.rmed.2020.105985
   PubMed Web of Science ®Google Scholar
• Athanazio RA, Bernal Villada L, Avdeev SN, et al. Rate of severe exacerbations, healthcare resource utilisation and clinical outcomes in patients with COPD in low-income and middle-income countries: results from the EXACOS international study. BMJ Open Respir Res. 2024;11(1):e002101. doi:10.1136/bmjresp-2023-002101
   PubMedGoogle Scholar
• Pernigotti D, Stonham C, Panigone S, et al. Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open Respir Res. 2021;8(1):e001071. doi:10.1136/bmjresp-2021-001071
   PubMed Web of Science ®Google Scholar
• Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur Respir J. 2020;55(5):2001122. doi: 10.1183/13993003.01122-2020
   PubMedGoogle Scholar
• Kponee-Shovein K, Marvel J, Ishikawa R, et al. Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation. J Med Econ. 2022;25(1):940–953. doi: 10.1080/13696998.2022.2088196
   PubMed Web of Science ®Google Scholar
• Jing QL, Liu HZ, Yu WQ, He X. The impact of public transportation on carbon emissions - From the perspective of energy consumption. Sustainability 2022;14:6248. Doi:10.3390/su14106248
   Google Scholar
• Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med. 2023;33(1):24. doi: 10.1038/s41533-023-00346-7
   PubMedGoogle Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi: 10.1016/j.rmed.2011.01.005
   PubMed Web of Science ®Google Scholar
• Tommelein E, Mehuys E, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 2014;77(5):756–766. doi: 10.1111/bcp.12242
   PubMed Web of Science ®Google Scholar
• Janjua S, Pike KC, Carr R, Coles A, Fortescue R, Batavia M. Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2021;9(9): CD013381. doi:10.1002/14651858.CD013381.pub2
   PubMedGoogle Scholar
• van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14(5):1034–1037. doi:10.1183/09031936.99.14510349
   PubMed Web of Science ®Google Scholar
• Rootmensen G, Keimpema A, Jansen H, Haan R. Predictors of incorrect inhalation technique in patients with asthma and COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010;23(5):1–6. doi:10.1089/jamp.2009.078520131983
   PubMedGoogle Scholar
• Duarte-de-Araújo A, Teixeira P, Hespanhol V, et al. COPD: misuse of inhaler devices in clinical practice. Int J Chron Obstruct Pulmon Dis. 2019;14:1209–1217. doi:10.2147/COPD.S178040
   PubMed Web of Science ®Google Scholar
• Barbara S, Kritikos V, Bosnic-Anticevich S. Inhaler technique: does age matter? A systematic review. Eur Respir Rev. 2017;26(146):170055. doi: 10.1183/16000617.0055-2017
   PubMed Web of Science ®Google Scholar
• Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF. Characteristics predicting incorrect metered-dose inhaler technique in older subjects. Arch Intern Med. 1996;156(9):984–988. doi:10.1001/archinte.1996.00440090084008
   PubMedGoogle Scholar
• Jones V, Fernandez C, Diggory P. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people. Age Ageing. 1999;28(5):481–484. doi:10.1093/ageing/28.5.481
   PubMed Web of Science ®Google Scholar
• Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18–25. doi: 10.1159/000109374
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi: 10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68(13):1221–1232. doi: 10.2146/ajhp100452
   PubMed Web of Science ®Google Scholar
• Dijk L, Kerkhof M, Driessen M, et al. Does mixing inhaler devices lead to unchecked inhaler technique errors in patients with COPD? Findings from the cross-sectional observational MISMATCH study. BMJ Open Respir Res. 2023;10(1):e001821. doi:10.1136/bmjresp-2023-001821
   PubMedGoogle Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. Impact of sex on proper use of inhaler devices in asthma and COPD: A systematic review and meta-analysis. Pharmaceutics. 2022;14(8):1565. doi:10.3390/pharmaceutics14081565 • A systematic review and meta-analysis that assessed the impact of sex on the proper use of inhaler devices in asthma and COPD.
   PubMedGoogle Scholar
• Harb HS, Ibrahim Laz N, Rabea H, et al. Determinants of incorrect inhaler technique in chronic obstructive pulmonary disease patients. Int J Clin Pract. 2021;75(6):e14073. doi: 10.1111/ijcp.14073
   PubMed Web of Science ®Google Scholar
• Tervonen T, Hawken N, Hanania NA, et al. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020;75(9):735–743. doi: 10.1136/thoraxjnl-2019-213974
   PubMed Web of Science ®Google Scholar
• Kim DD, Basu A. How does cost-effectiveness analysis inform health care decisions? AMA J Ethics. 2021;23(8):E639–E647. doi:10.1001/amajethics.2021.639
   Google Scholar
• Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. doi:10.1002/14651858.MR000033.pub2
   PubMed Web of Science ®Google Scholar
• Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009;27(11):903–917. doi: 10.2165/10899580-000000000-00000
   PubMed Web of Science ®Google Scholar
• Griffiths UK, Legood R, Pitt C. Comparison of economic evaluation methods across low-income, middle-income and high-income countries: What are the differences and why. Health Econ. 2016; 25 Suppl 1(Suppl Suppl 1):29–41. doi:10.1002/hec.3312
   Google Scholar